Clinical trials: completed, sponsored by AbbVie
Healthy Volunteer
A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants
This is a Phase 1, first-in-human study to investigate safety, tolerability, and pharmacokinetics of ABBV-722 after oral dosing in healthy adult participants.
- Trial name
- NCT06673238
- Testing
- ABBV-722
- Where
- 2 sites in United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- AbbVie
Cancer - Chronic Lymphocytic Leukemia
Study Venetoclax Effectiveness and Real-Life Treatment Management in Participants With Chronic Lymphocytic Leukemia
This study will evaluate real-life effectiveness and use in participants starting venetoclax treatment for Chronic Lymphocytic Leukemia (CLL).
- Trial name
- VERONE (NCT03415035)
- Where
- 60 sites in France
- Volunteers
- 269 people
- Sponsor
- AbbVie
Healthy Volunteer
A Study to Assess How the Body Absorbs ABBV-8736 Subcutaneous Injections Relative to Intravenous Injections in Adult Healthy Volunteers
The purpose of this study is to assess the pharmacokinetics (PK), bioavailability, immunogenicity, safety, and tolerability of ABBV-8736 following subcutaneous (SC) administration relative to intravenous (IV) administration.
- Trial name
- NCT07413133
- Testing
- ABBV-8736
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteer
A Study to Assess Adverse Events, Tolerability and How a Single Oral Dose of Nacresertib Moves Through the Body In Healthy Adult Japanese Participants
A Study to Assess Adverse Events, Tolerability and How a Single Oral Dose of Nacresertib Moves Through the Body In Healthy Adult Japanese Participants
- Trial name
- NCT07600762
- Testing
- Nacresertib
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AbbVie
Open-Angle Glaucoma, Ocular Hypertension
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
This study will evaluate the long-term safety and efficacy of Bimatoprost Sustained Release (SR) in patients with open-angle glaucoma or ocular hypertension who completed 1 of the 4 Phase 3 Bimatoprost SR studies (192024-091…
- Trial name
- MAIA (NCT03891446)
- Testing
- Bimatoprost SR, Standard of Care
- Where
- 124 sites in United States, Argentina and 24 more
- Volunteers
- 455 people
- Sponsor
- AbbVie
Healthy Volunteers
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Participants
The objective of this study is to evaluate the safety, tolerability, immunogenicity and pharmacokinetics (PK ) properties following a single dose of ABBV-277 in healthy adult participants.
- Trial name
- NCT07136103
- Testing
- ABBV-277
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- AbbVie
Masseter Muscle Prominence
A Study to Assess Adverse Events and Change of Masseter Muscle Prominence Using BOTOX Injections in Adult Participants
The masseter muscle is one of the muscles in the lower face used for chewing. Prominence of the masseter muscle can appear as a widened and square lower face shape, which is an aesthetic concern for individuals who prefer a…
- Trial name
- MMP Japan 080 (NCT06137287)
- Testing
- BOTOX
- Where
- 18 sites in Japan
- Volunteers
- 259 people
- Sponsor
- AbbVie
Migraine
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine
A migraine is a moderate to severe headache on one side of the head that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms.
- Trial name
- ATO-TOPIRAMATE (NCT05748483)
- Testing
- Atogepant, Topiramate
- Where
- 81 sites in Austria, Belgium and 10 more
- Volunteers
- 545 people
- Sponsor
- AbbVie
Non-Surgical Fat Reduction
A Study to Assess Non-Invasive Subcutaneous Fat Reduction in the Submental, Inner Thigh and Back/Bra Areas With the CoolSculpting Elite System
The primary objective of this protocol is the continued collection of data specific to the submental, inner thigh and back/bra body areas with CoolSculpting Elite.
- Trial name
- NCT07122583
- Testing
- CoolSculpting Elite System
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- AbbVie
Migraine
Study to Assess Function and Satisfaction of Oral Ubrogepant in Adult Participants After Multiple Migraine Attacks In Canada
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound.
- Trial name
- NCT06692881
- Where
- 13 sites in Canada
- Volunteers
- 178 people
- Sponsor
- AbbVie
Glabellar Lines
A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin.
- Trial name
- NCT05496335
- Testing
- AGN-151586, BOTOX
- Where
- 10 sites in United States
- Volunteers
- 90 people
- Sponsor
- AbbVie
Glabellar Lines
A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar Lines
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin.
- Trial name
- NCT06308198
- Testing
- AGN-151586
- Where
- 12 sites in China, Japan and 1 more
- Volunteers
- 161 people
- Sponsor
- AbbVie
Moderate to Severe Glabellar Lines
Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar Lines
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin.
- Trial name
- NCT06151561
- Testing
- AGN-151586
- Where
- Japan
- Volunteers
- 24 people
- Sponsor
- AbbVie
Atopic Dermatitis
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)
The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
- Trial name
- Measure Up 1 (NCT03569293)
- Testing
- Upadacitinib
- Where
- 180 sites in United States, Argentina and 23 more
- Volunteers
- 912 people
- Sponsor
- AbbVie
Chronic Migraine
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine
Migraine is characterized by attacks of throbbing, moderate or severe headache, often associated with nausea, vomiting, and/or sensitivity to light and/or sound.
- Trial name
- ATO-BOTOX (NCT05216263)
- Testing
- Atogepant
- Where
- 29 sites in United States
- Volunteers
- 75 people
- Sponsor
- AbbVie
Migraine
Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine
A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms.
- Trial name
- JPN PIVOTAL (NCT05861427)
- Testing
- Atogepant
- Where
- 48 sites in Japan
- Volunteers
- 524 people
- Sponsor
- AbbVie
Healthy Volunteers
A Study to Assess Adverse Events, Tolerability and How Single and Ascending Oral Doses of Nacresertib Move Through the Body In Healthy Adult Participants
The objectives for this 2 Part study are to assess the safety, tolerability, and pharmacokinetics following single ascending oral doses of nacresertib in healthy adult participants (Part 1) and to assess the safety, tolerability…
- Trial name
- NCT07566130
- Testing
- nacresertib
- Where
- United States
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteer
A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants
This study will assess the relative bioavailability and effect of food on pharmacokinetics of ABBV-932 oral administration in healthy adult participants.
- Trial name
- NCT06849791
- Testing
- ABBV-932
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- AbbVie
Migraine
An Observational Study to Assess Change in Disease Activity When Ubrogepant Tablets Are Combined With Atogepant Tablets to Treat Migraine in Adult Participants
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound.
- Trial name
- COURAGE II (NCT05653986)
- Where
- United States
- Volunteers
- 391 people
- Sponsor
- AbbVie
Rheumatoid Arthritis (RA)
Study To Assess Frequency Of Serious Infections In Clinical Practice In Japan For Adult Participants With Rheumatoid Arthritis Receiving Oral RINVOQ Tablets
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. RA can reduce the ability to perform everyday tasks.
- Trial name
- NCT04340115
- Where
- 1,017 sites in Japan
- Volunteers
- 4,211 people
- Sponsor
- AbbVie